Improving metabolic control in sub-optimally controlled subjects with Type 1 diabetes: Comparison of two treatment algorithms using insulin glargine

Diabetes Research and Clinical Practice

Volumn 77, Issue 1, 2007, Pages 84-91

  Gomis, Ramon ^a   Storms, Fred ^b   Conget, Ignacio ^a   Sinnassamy, Patrick ^c   Davies, Melanie ^d  

^a HOSPITAL CLÍNIC   (Spain)

^b Mesos Diabetes Centrum   (Netherlands)

^c SANOFI   (France)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Basal insulin analogues; Insulin glargine; Titration; Treatment algorithms; Type 1 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; METABOLIC REGULATION; MULTICENTER STUDY; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; SEIZURE; TREATMENT OUTCOME; VISUAL DISORDER; WEIGHT GAIN;

ADULT; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 34247098348     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.10.002     Document Type: Article

References (19)

1. Porcellati F., Rossetti P., Pampanelli S., Fanelli C.G., Torlone E., Scionti L., et al. Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin. Diab. Med. 21 (2004) 1213-1220
2. The American Association of Clinical Endocrinologists. Medical guidelines for the management of diabetes mellitus: the AACE system of intensive diabetes self-management-2000 update. Endocr. Pract. 6 (2000) 43-84
3. Cryer P. Hypoglycemia is the limiting factor in the management of diabetes. Diab. Metab. Res. Rev. 15 (1999) 42-46
4. DeWitt D.E., and Hirsch I.B. Outpatient insulin therapy in Type 1 and Type 2 diabetes mellitus: scientific review. JAMA 289 (2003) 2254-2264
5. Home P.D., Rosskamp R., Forjanic-Klapproth J., and Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with Type 1 diabetes. Diab. Metab. Res. Rev. 21 (2005) 545-553
6. Raskin P., Klaff L., Bergenstal R., Halle J.P., Donley D., and Mecca T. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with Type 1 diabetes. Diab. Care 23 (2000) 1666-1671
7. Ashwell S.G., Amiel S.A., Bilous R.W., Dashora U., Heller S.R., Hepburn D.A., et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diab. Med. 23 (2006) 285-292
8. Rossetti P., Pampanelli S., Fanelli C., Porcellati F., Costa E., Torlone E., et al. Intensive replacement of basal insulin in patients with Type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diab. Care 26 (2003) 1490-1496
9. Fulcher G.R., Gilbert R.E., and Yue D.K. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Int. Med. J. 35 (2005) 536-542
10. ® prescribing information, 2003.
11. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46 (1997) 271-286
12. The Diabetes Control and Complications Trial Research Group. Epidemiology of severe hypoglycemia in the Diabetes Control and Complications Trial. Am. J. Med. 90 (1991) 450-459
13. Davies M., Storms F., Shutler S., Bianchi-Biscay M., and Gomis R. Improvement of glycemic control in subjects with poorly controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diab. Care 28 (2005) 1282-1288
14. Hillman N., Herranz L., Grande C., Villaroel A., and Pallardo L.F. Is HbA(1c) influenced more strongly by preprandial or postprandial glycemia in Type 1 diabetes?. Diab. Care 25 (2002) 1100-1101
15. 1c in Type 1 diabetes?. Diab. Med. 21 (2004) 468-470
16. Bailar J.C. The powerful placebo and the Wizard of Oz. N. Engl. J. Med. 344 (2001) 1630-1632
17. Rosenstock J., Park G., and Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diab. Care 23 (2000) 1137-1142
18. Fanelli C.G., Porcellati F., Pampanelli S., and Bolli G.B. Insulin therapy and hypoglycaemia: the size of the problem. Diab. Metab. Res. Rev. 20 Suppl. 2 (2004) S32-S42
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329 (1993) 977-986